April 30, 2014—Federal 340B contract pharmacy guidance “does not specify” whether covered entities are responsible for ensuring that states do not collect manufacturer rebates for 340B-purchased drugs reimbursed by Medicaid managed care organizations, the Department of Health and Human Services Office of Inspector General says in a letter to two 340B provider groups.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)